Dr. Stephen Fremes, MD
Claim this profileSunnybrook Health Sciences Centre
Studies Coronary Artery Disease
Studies Heart Disease
5 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Stephen Fremes, MD is currently running
Heart Surgery
for Coronary Artery Disease
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Recruiting1 award N/A4 criteria
Single vs Multiple Arterial Grafts
for Heart Disease
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups.
Recruiting1 award N/A4 criteria
More about Stephen Fremes, MD
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Stephen Fremes, MD has experience with
- Revascularization By CABG
- Revascularization By PCI
- Multiple Arterial Grafting
- Single Arterial Graft
- Multiple Arterial Grafting
- Single Arterial Graft
Breakdown of trials Stephen Fremes, MD has run
Coronary Artery Disease
Heart Disease
Heart Failure
Cardiomyopathy
Coronary Artery Bypass Surgery
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen Fremes, MD specialize in?
Stephen Fremes, MD focuses on Coronary Artery Disease and Heart Disease. In particular, much of their work with Coronary Artery Disease has involved treating patients, or patients who are undergoing treatment.
Is Stephen Fremes, MD currently recruiting for clinical trials?
Yes, Stephen Fremes, MD is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Stephen Fremes, MD has studied deeply?
Yes, Stephen Fremes, MD has studied treatments such as Revascularization by CABG, Revascularization by PCI, Multiple arterial grafting.
What is the best way to schedule an appointment with Stephen Fremes, MD?
Apply for one of the trials that Stephen Fremes, MD is conducting.
What is the office address of Stephen Fremes, MD?
The office of Stephen Fremes, MD is located at: Sunnybrook Health Sciences Center, Toronto, Ontario M4N 3M5 Canada. This is the address for their practice at the Sunnybrook Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.